Cargando…

Rilonacept (IL-1 TRAP) for treatment of colchicine resistant familial mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial

Detalles Bibliográficos
Autores principales:	Hashkes, PJ, Spalding, SJ, Giannini, EH, Huang, B, Park, G, Barron, KS, Weisman, MH, Pashinian, N, Reiff, AO, Samuels, J, Wright, D, Kastner, DL, Lovell, DJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194434/ http://dx.doi.org/10.1186/1546-0096-9-S1-O38

Ejemplares similares

The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever
por: Hashkes, Philip J., et al.
Publicado: (2014)

The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine resistant or intolerant FMF
por: Hashkes, P, et al.
Publicado: (2015)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

Colchicine therapy in children with FMF
por: Knieper, A-M, et al.
Publicado: (2015)

Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
por: Salehzadeh, Farhad, et al.
Publicado: (2019)

Colchicine treatment can be discontinued in a selected group of pediatric FMF patients
por: Cohen, Keren, et al.
Publicado: (2023)

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022)

P01-031 – Anakinra for colchicine resistant FMF
por: Ben-Zvi, I, et al.
Publicado: (2013)

PW01-025 – Definition of colchicine resistance in FMF
por: Demirkaya, E, et al.
Publicado: (2013)

Developing of a new scale for assessing the adherence to colchicine treatment in pediatric patients with FMF
por: Yesilkaya, S, et al.
Publicado: (2015)

Correction to: Rilonacept (Interleukin‑1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022)

PW01-006 – The effect of colchicine on physical growth in FMF
por: Cakar, N, et al.
Publicado: (2013)

PW01-002 – Colchicine resistant FMF in Turkish children
por: Eroglu, FK Kara, et al.
Publicado: (2013)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

PW01-007 – Colchicine brand switching in FMF patients
por: Jagger, J, et al.
Publicado: (2013)

PW01-005 – Effects of placebo and colchicine on FMF patients
por: Özaltın, F, et al.
Publicado: (2013)

Colchicine intolerance in FMF patients and primary obstacles for optimal dosing
por: SATIŞ, Hasan, et al.
Publicado: (2020)

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
por: El Hasbani, Georges, et al.
Publicado: (2019)

PReS-FINAL-2218: Treatment of colchicines resistant FMF: experience of a pediatric center in Turkey
por: Kara Eroglu, F, et al.
Publicado: (2013)

Toll like receptor 2 is overexpressed in FMF patients during attacks and inhibited by colchicine treatment
por: Ben-David, H, et al.
Publicado: (2015)

P01-009 – 2 years of colchicine IV in intractable FMF
por: Kaly, L, et al.
Publicado: (2013)

P01-027 – Normal HRV in colchicine-resistant FMF patients
por: Nussinovitch, U, et al.
Publicado: (2013)

The patient experience of Colchicine Resistant-Familial Mediterranean Fever (cr-FMF)
por: Dandekar, P, et al.
Publicado: (2015)

The effect of Anakinra on Quality-of-Life in a family with colchicine-resistant FMF
por: van der Hilst, J, et al.
Publicado: (2015)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

Epidemiology of colchicine resistant Familial Mediterranean Fever disease (CrFMF) in Turkey
por: Turgay, S, et al.
Publicado: (2015)

Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF
por: Pinchevski-Kadir, Shiran, et al.
Publicado: (2023)

PReS-FINAL-2204: Developing of a new scale for assessing the adherence to colchicines treatment in pediatric patients with FMF
por: Yesilkaya, S, et al.
Publicado: (2013)

Factors affecting cardiovascular morbidity in young FMF patients. A comparative analysis in colchicine treated FMF patients with and without cardiovascular disease
por: Roitman, AJ, et al.
Publicado: (2015)

Further reassurance on the safety profile of colchicine
por: Hashkes, Philip J.
Publicado: (2020)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Compliance to colchicine treatment and disease activity in Familial Mediterranean Fever (FMF) patients in Middle/Black Sea Region of Turkey (in Çorum region)
por: Karaaslan, Y, et al.
Publicado: (2015)

7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis
por: Giannini, EH, et al.
Publicado: (2008)

PReS-FINAL-2328: Developing and validating the new severity score for FMF
por: Demirkaya, E, et al.
Publicado: (2013)

PW01-028 – Developing a new severity score for FMF
por: Demirkaya, E, et al.
Publicado: (2013)

Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis
por: Affas, Ziad R, et al.
Publicado: (2022)

Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
por: Brucato, Antonio, et al.
Publicado: (2023)

PW01-018 – Circulating endothelial biomarkers in FMF
por: Sari, I, et al.
Publicado: (2013)

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator
por: Terkeltaub, Robert A, et al.
Publicado: (2013)

Intestinal malrotation as a misdiagnosis of pediatric colchicine resistant familial Mediterranean fever
por: Heshin-Bekenstein, Merav, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nfm7v34e995545i353gemd7anj